Annual EBITDA
$1.89 B
+$1.46 B+345.43%
31 December 2023
Summary:
Royalty Pharma annual earnings before interest, taxes, depreciation & amortization is currently $1.89 billion, with the most recent change of +$1.46 billion (+345.43%) on 31 December 2023. During the last 3 years, it has risen by +$456.94 million (+31.95%). RPRX annual EBITDA is now -31.47% below its all-time high of $2.75 billion, reached on 31 December 2019.RPRX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
$872.86 M
+$629.47 M+258.63%
30 September 2024
Summary:
Royalty Pharma quarterly earnings before interest, taxes, depreciation & amortization is currently $872.86 million, with the most recent change of +$629.47 million (+258.63%) on 30 September 2024. Over the past year, it has increased by +$108.02 million (+14.12%). RPRX quarterly EBITDA is now -42.41% below its all-time high of $1.52 billion, reached on 31 December 2019.RPRX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$1.92 B
+$704.75 M+57.94%
30 September 2024
Summary:
Royalty Pharma TTM earnings before interest, taxes, depreciation & amortization is currently $1.92 billion, with the most recent change of +$704.75 million (+57.94%) on 30 September 2024. Over the past year, it has increased by +$33.78 million (+1.79%). RPRX TTM EBITDA is now -35.70% below its all-time high of $2.99 billion, reached on 30 September 2020.RPRX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RPRX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +14.1% | +1.8% |
| 3 y3 years | +31.9% | +720.0% | +34.3% |
| 5 y5 years | -31.5% | -42.4% | -30.2% |
RPRX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +345.4% | at high | +255.0% | at high | +353.4% |
| 5 y | 5 years | -31.5% | +345.4% | -42.4% | +255.0% | -35.7% | +353.4% |
| alltime | all time | -31.5% | +345.4% | -42.4% | +255.0% | -35.7% | +353.4% |
Royalty Pharma EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $872.86 M(+258.6%) | $1.92 B(+57.9%) |
| June 2024 | - | $243.39 M(+509.1%) | $1.22 B(-11.3%) |
| Mar 2024 | - | $39.96 M(-94.8%) | $1.37 B(-27.3%) |
| Dec 2023 | $1.89 B(+345.4%) | $764.84 M(+355.0%) | $1.89 B(+237.4%) |
| Sept 2023 | - | $168.11 M(-57.8%) | $559.36 M(-15.1%) |
| June 2023 | - | $398.29 M(-28.4%) | $658.64 M(-17.6%) |
| Mar 2023 | - | $556.04 M(-198.8%) | $798.92 M(+88.6%) |
| Dec 2022 | $423.69 M(-70.4%) | -$563.08 M(-310.6%) | $423.69 M(-61.2%) |
| Sept 2022 | - | $267.39 M(-50.4%) | $1.09 B(-0.4%) |
| June 2022 | - | $538.56 M(+197.9%) | $1.10 B(-22.1%) |
| Mar 2022 | - | $180.82 M(+69.9%) | $1.41 B(-1.5%) |
| Dec 2021 | $1.43 B | $106.44 M(-60.9%) | $1.43 B(-17.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | $271.92 M(-68.0%) | $1.73 B(-18.3%) |
| June 2021 | - | $849.91 M(+320.6%) | $2.12 B(+10.9%) |
| Mar 2021 | - | $202.06 M(-50.7%) | $1.92 B(+1.8%) |
| Dec 2020 | $1.88 B(-31.7%) | $410.27 M(-38.0%) | $1.88 B(-37.0%) |
| Sept 2020 | - | $661.49 M(+3.1%) | $2.99 B(+5.2%) |
| June 2020 | - | $641.90 M(+281.1%) | $2.84 B(+15.8%) |
| Mar 2020 | - | $168.41 M(-88.9%) | $2.45 B(-10.9%) |
| Dec 2019 | $2.75 B(+50.4%) | $1.52 B(+194.5%) | $2.75 B(+122.4%) |
| Sept 2019 | - | $514.62 M(+102.9%) | $1.24 B(+71.1%) |
| June 2019 | - | $253.67 M(-46.0%) | $723.63 M(+54.0%) |
| Mar 2019 | - | $469.96 M | $469.96 M |
| Dec 2018 | $1.83 B(+12.8%) | - | - |
| Dec 2017 | $1.62 B | - | - |
FAQ
- What is Royalty Pharma annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Royalty Pharma?
- What is Royalty Pharma quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Royalty Pharma?
- What is Royalty Pharma quarterly EBITDA year-on-year change?
- What is Royalty Pharma TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Royalty Pharma?
- What is Royalty Pharma TTM EBITDA year-on-year change?
What is Royalty Pharma annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of RPRX is $1.89 B
What is the all time high annual EBITDA for Royalty Pharma?
Royalty Pharma all-time high annual earnings before interest, taxes, depreciation & amortization is $2.75 B
What is Royalty Pharma quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of RPRX is $872.86 M
What is the all time high quarterly EBITDA for Royalty Pharma?
Royalty Pharma all-time high quarterly earnings before interest, taxes, depreciation & amortization is $1.52 B
What is Royalty Pharma quarterly EBITDA year-on-year change?
Over the past year, RPRX quarterly earnings before interest, taxes, depreciation & amortization has changed by +$108.02 M (+14.12%)
What is Royalty Pharma TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of RPRX is $1.92 B
What is the all time high TTM EBITDA for Royalty Pharma?
Royalty Pharma all-time high TTM earnings before interest, taxes, depreciation & amortization is $2.99 B
What is Royalty Pharma TTM EBITDA year-on-year change?
Over the past year, RPRX TTM earnings before interest, taxes, depreciation & amortization has changed by +$33.78 M (+1.79%)